safinamide   Click here for help

GtoPdb Ligand ID: 8291

Synonyms: EMD 1195686 | EMD-1195686 | Xadago®
Approved drug
safinamide is an approved drug (EMA (2015), FDA (2017))
Compound class: Synthetic organic
Comment: Safinamide is an alpha-aminoamide. The clinically administered formulation may be the mesylate salt (PubChem CID 3038502).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 64.35
Molecular weight 302.14
XLogP 2.5
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES NC(=O)C(NCc1ccc(cc1)OCc1cccc(c1)F)C
Isomeric SMILES NC(=O)[C@@H](NCc1ccc(cc1)OCc1cccc(c1)F)C
InChI InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
No information available.
Summary of Clinical Use Click here for help
Safinamide is approved as an adjunct to dopamine agonist or levodopa/carbidopa therapy in patients with Parkinson's disease experiencing "off" episodes.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Safinamide's main action is to inhibit monoamine oxidase B (MAOB) which reduces degradation of dopamine [3], but may also inhibit reuptake of dopamine and act to inhibit glutamate release, and block sodium and calcium channels. Inhibition of MAOB effectively increases dopamine levels in the brain, providing some relief from the motor symptoms of Parkinson's disease. The drug helps to reduce the motor fluctuations which can occur when the effect of levodopa therapy wears off.
External links Click here for help